Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to transforming the lives of patients with serious diseases through innovative medicines. With a diverse portfolio in neuroscience and oncology, Jazz focuses on developing life-changing medicines for conditions with limited or no options, exploring small molecules, biologics, and innovative delivery technologies. The company emphasizes integrity, collaboration, passion, innovation, and pursuit of excellence, and operates in nearly 75 countries. The company is actively involved in advancing science in areas such as HER2-positive cancers, aiming to improve treatment options for patient communities with significant unmet needs. Recent advancements include the development of bispecific antibodies targeting HER2-expressing cancers, which offer a novel approach to treating solid tumors, including potential first-line treatments. Jazz also supports biliary tract cancer patients through advocacy partnerships, emphasizing patient-centered care and insights to inform R&D efforts.
Industries
Nr. of Employees
large (251-1000)
Jazz Pharmaceuticals
3170 Porter Dr., Palo Alto, California 94304
Patents
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-11207270-B2
View DetailsControlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-11090269-B1
View DetailsControlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-10987310-B2
View DetailsControlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-10966931-B2
View Details
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-11207270-B2
View DetailsControlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-11090269-B1
View DetailsControlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-10987310-B2
View DetailsControlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US-10966931-B2
View DetailsProducts
Cannabidiol‑based marketed therapeutic (anticonvulsant)
Marketed cannabidiol‑based medicine referenced on the company site; classified here by therapeutic modality rather than brand name.
Sodium oxybate formulation (marketed)
Marketed sodium oxybate formulation referenced on the company site; described generically to avoid use of brand names.
Multi‑cation oxybate formulation (marketed)
Marketed oxybate formulation with multiple cations referenced on the company site; presented without brand identifiers.
Defibrotide sodium (marketed)
Marketed defibrotide sodium product referenced on the company site; categorized by active ingredient.
Recombinant Erwinia asparaginase (marketed)
Recombinant Erwinia asparaginase product referenced on the company site; presented without brand naming.
Combination daunorubicin–cytarabine chemotherapy (marketed)
Combination chemotherapy product referenced on the company site; listed by active components rather than brand.
Cannabidiol‑based marketed therapeutic (anticonvulsant)
Marketed cannabidiol‑based medicine referenced on the company site; classified here by therapeutic modality rather than brand name.
Sodium oxybate formulation (marketed)
Marketed sodium oxybate formulation referenced on the company site; described generically to avoid use of brand names.
Multi‑cation oxybate formulation (marketed)
Marketed oxybate formulation with multiple cations referenced on the company site; presented without brand identifiers.
Defibrotide sodium (marketed)
Marketed defibrotide sodium product referenced on the company site; categorized by active ingredient.
Recombinant Erwinia asparaginase (marketed)
Recombinant Erwinia asparaginase product referenced on the company site; presented without brand naming.
Combination daunorubicin–cytarabine chemotherapy (marketed)
Combination chemotherapy product referenced on the company site; listed by active components rather than brand.
Services
Evaluation and management of in‑licensing proposals, collaboration opportunities and strategic partnerships with an established intake process for opportunity submissions and deal assessment.
Centralized handling of medical information requests and product inquiries in local languages through regional contact centers and online portals.
Services to assist patients with access to therapies and to provide program information, including helplines and regional support portals.
Site‑based manufacturing operations combined with formulation and process development to support clinical and commercial production and supply chain resilience.
Regulatory‑compliant channels and processes for reporting adverse events and product complaints, with centralized workflows to support regulatory submissions and inquiries.
Evaluation and management of in‑licensing proposals, collaboration opportunities and strategic partnerships with an established intake process for opportunity submissions and deal assessment.
Centralized handling of medical information requests and product inquiries in local languages through regional contact centers and online portals.
Services to assist patients with access to therapies and to provide program information, including helplines and regional support portals.
Site‑based manufacturing operations combined with formulation and process development to support clinical and commercial production and supply chain resilience.
Regulatory‑compliant channels and processes for reporting adverse events and product complaints, with centralized workflows to support regulatory submissions and inquiries.
Expertise Areas
- Clinical trial management
- Post‑marketing surveillance and real‑world evidence
- Targeted oncology biologics development (including bispecific formats)
- Neuroscience and sleep‑disorder therapeutics
Key Technologies
- Bispecific antibody therapeutics
- HER2‑targeted antibody approaches
- Small‑molecule drug discovery methods
- Cannabinoid therapeutic modalities